<![CDATA[Why CAR T-Cell Therapy Should Precede Bispecifics in Multiple Myeloma ]]>

Summary

Expert physicians Joshua Richter and Marco Davila discuss the optimal sequencing of CAR T-cell therapy and bispecific antibodies in multiple myeloma treatment. This is an expert commentary piece without clinical trial data or regulatory outcomes.